Latest in Biodefense
If Joe Biden wins the November election, Americans will likely see a reversion to a more traditional approach to the presidency. What might that mean in the field of U.S. national security?
The FBI and CISA are worried about intellectual property theft of coronavirus vaccines and treatments. But to develop cures quickly, the scientific community needs to think cooperatively.
If Congress is serious about bending the curve, it shouldn’t allow people to opt out of effective disease-surveillance programs.
Russia initially seemed largely unscathed by the pandemic. But the virus has since arrived in full force. How has the country responded?
The Canadian military reassesses its overseas footprint in response to COVID-19, and the Liberal government comes under pressure to adjust its China policy.
The legendary Yangyang Cheng discusses how Coronavirus played out in cross-continent conversations with her mother. We'll also hear from Asmod in Nepal and Lambert in Singapore.
There are long-overlooked dangers embedded within the adoption of digital technologies—and as society shifts online during the pandemic, consumers and policymakers must figure out how to address those risks.
Conflicting statements from U.S. leaders are undercutting the credibility of U.S. intelligence on the coronavirus.
While Beijing’s responsibility for violations of international legal obligations seems evident, International Court of Justice precedent on causality and reparations will probably thwart any efforts to make China pay compensation for damages caused by the coronavirus.
In the U.S., efforts to develop digital contact-tracing systems have largely fallen to states and tech companies—though privacy advocates have voiced concerns about the invasiveness of such apps.